Cancer Vaccines

ImClone, Bristol-Myers Squibb Seek FDA Approval Of Erbitux

Published in Vaccine Weekly, November 21st, 2001

ImClone Systems, Inc., (IMCL) and Bristol-Myers Squibb Co. (BMY) have completed their rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for approval of Erbitux (formerly known as IMC-C225) for the treatment of irinotecan-refractory colorectal cancer.

Erbitux is an investigational monoclonal antibody designed to target and block the epidermal growth factor receptor (EGFR), which is expressed on the surface of certain cancer cells, including colon cancer. Bristol-Myers Squibb and ImClone Systems recently announced an agreement to codevelop and copromote Erbitux in the United States, Canada, and Japan.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry